Showing results (121-130 of 158) with videos related to

Sort By:
Pageof 16
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 20, 2019
Word-finding difficulty is a prevalent disease-related deficit in early multiple sclerosisRachel Brandstadter, Michelle Fabian, Victoria M Leavitt, et al.
Neurology. Clinical Practice|June 24, 2022
Confirming a Historical Diagnosis of Multiple Sclerosis: Challenges and RecommendationsAndrew J Solomon, Georgina Arrambide, Wallace Brownlee, et al.
The Lancet. Neurology|November 23, 2020
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce A C Cree, Gary Cutter, Jerry S Wolinsky, et al.
Annals of Clinical and Translational Neurology|May 5, 2021
Sleep disturbance and memory dysfunction in early multiple sclerosisJames F Sumowski, Sam Horng, Rachel Brandstadter, et al.
Brain : a Journal of Neurology|February 1, 2022
How patients with multiple sclerosis acquire disabilityFred D Lublin, Dieter A Häring, Habib Ganjgahi, et al.
The New England Journal of Medicine|March 3, 2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick, William H Stuart, Peter A Calabresi, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2023
Do the current MS clinical course descriptors need to change and if so how? A survey of the MS communityAlan J Thompson, Marcello Moccia, Maria Pia Amato, et al.
The New England Journal of Medicine|March 3, 2006
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisChris H Polman, Paul W O'Connor, Eva Havrdova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosisGiancarlo Comi, Yuval Dadon, Nissim Sasson, et al.
Pageof 16